Epocrates, Inc. (NASDAQ:EPOC)

CAPS Rating: 5 out of 5

Recs

1
Player Avatar TMFIPO2011 (< 20) Submitted: 7/6/2011 1:21:55 PM : Outperform Start Price: $17.57 EPOC Score: -89.08

**Physicians love Epocrates' mobile applications, because they reduce prescription errors, improve patient care, and save time.
**Epocrates is disrupting the face-to-face sales model used by pharma companies by offering a more targeted and cost-effective way to introduce physicians to new and existing drugs.
**The company has ridden its first-mover advantage to an 80% market share that reaches 45% of all U.S. physicians, and it benefits from a recurring revenue base to fund R&D for new products.

Member Avatar PshawFool (< 20) Submitted: 7/12/2011 12:01:29 AM
Recs: 0

Epocrates announced the appointment of Matthew Kaminer as general counsel and secretary of Epocrates, effective June 27, 2011. Mr. Kaminer succeeds Paul Banta, who has resigned as executive vice president, general counsel and secretary, effective July 1, 2011 to pursue other interests.

What is the reason for the management change? Does the change affect the Stock Advisor recommendation?

PshawFool

Featured Broker Partners


Advertisement